Naming Convention, Interchangeability, and Patient Interest in Biosimilars
暂无分享,去创建一个
[1] Jace B. Garrett,et al. Consumer Responses to Price Disclosure in Direct-to-Consumer Pharmaceutical Advertising , 2019, JAMA internal medicine.
[2] J. Curtis,et al. Patient attitudes about non-medical switching to biosimilars: results from an online patient survey in the United States , 2019, Current medical research and opinion.
[3] M. Ernst,et al. Switching from Reference to Biosimilar Products: An Overview of the European Approach and Real-World Experience So Far , 2018, EMJ Rheumatology.
[4] G. Tang. Rationale, Opportunities, and Reality of Biosimilar Medications. , 2018, The New England journal of medicine.
[5] R. Schilsky,et al. Rationale, Opportunities, and Reality of Biosimilar Medications , 2018, The New England journal of medicine.
[6] J. Daller. Biosimilars: A consideration of the regulations in the United States and European union. , 2016, Regulatory toxicology and pharmacology : RTP.
[7] Jared Eutsler,et al. Rating Scales in Accounting Research: The Impact of Scale Points and Labels , 2015 .
[8] T. Brennan,et al. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers. , 2015, Health affairs.
[9] J. Trouvin,et al. Biosimilars and the European experience: implications for the United States. , 2013, Health affairs.
[10] Lydia B. Chilton,et al. The labor economics of paid crowdsourcing , 2010, EC '10.
[11] David P Mackinnon,et al. Confidence Limits for the Indirect Effect: Distribution of the Product and Resampling Methods , 2004, Multivariate behavioral research.